– The THRIVE-2 world part 3 medical trial evaluated the efficacy and security of veligrotug in sufferers with power thyroid eye illness (TED) –
– Convention name and webcast to happen on Monday, December 16 at 8 a.m. ET –
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical firm targeted on the invention and improvement of first-in-class drug candidates for severe and uncommon ailments, right now introduced its intention to arrange a convention name and webcast to report key knowledge from the THRIVE-2 part 3 medical trial, evaluating veligrotug in power PDD, on Monday, December 16 2024 at 8:00 a.m. ET.
Details about convention calls and webcasts
The webcast could be accessed beneath Occasions & Displays within the Buyers part of Viridian’s web site at viridiantherapeutics.com. To take part within the convention name, please dial 800-715-9871 (home) or 646-307-1963 (worldwide) and reference code 9934051. A replay of the webcast will probably be out there after the occasion has concluded.
About Viridian Therapeutics
Viridian is a biopharmaceutical firm targeted on the engineering and improvement of potential first-in-class medicines for sufferers with severe and uncommon ailments. Viridian’s experience in antibody discovery and protein engineering permits the event of differentiated therapeutic candidates for beforehand validated drug targets in commercially established illness areas.
Viridian has a number of candidates within the clinic for the therapy of sufferers with thyroid eye illness (TED). The Firm is conducting a pivotal program for veligrotug (VRDN-001), together with two world Section 3 medical trials (THRIVE and THRIVE-2), to judge its efficacy and security in sufferers with lively and power TED. Viridian can also be advancing VRDN-003 as a possible first-in-class subcutaneous remedy for the therapy of TED, together with two ongoing world pivotal Section 3 medical trials, REVEAL-1 and REVEAL-2, to judge the effectiveness and security of VRDN-003. 003 in sufferers with lively and power TED.
Along with its TED portfolio, Viridian is creating a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, together with VRDN-006 and VRDN-008, which have the potential for improvement in a number of autoimmune ailments.
Viridian relies in Waltham, Massachusetts. For extra info, please go to www.viridiantherapeutics.com. Observe Viridian on LinkedIn And X.
Ahead-looking statements
This press launch accommodates forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. These statements could be recognized by way of phrases comparable to, however not restricted to, anticipate, consider, proceed, might, estimate , anticipate. , intend, might, might, on observe, plan, potential, predict, undertaking, design, ought to, goal, will or would or different comparable phrases or expressions that relate to our expectations, plans and intentions. Ahead-looking statements are neither historic info nor ensures of future efficiency. As an alternative, they’re based mostly on our present beliefs, expectations, and assumptions. Ahead-looking statements embody, however usually are not restricted to, statements relating to: the preclinical and medical improvement of Viridian’s product candidates, veligrotug (previously VRDN-001), VRDN-003, VRDN-006 and VRDN-008; Viridian’s product candidates are doubtlessly best-in-class; and the event potential of Viridian’s product candidates in a number of autoimmune ailments.
New dangers and uncertainties might emerge occasionally, and it’s not potential to foretell all dangers and uncertainties. No illustration or guarantee (specific or implied) is made as to the accuracy of those forward-looking statements. These forward-looking statements are topic to a variety of necessary dangers and uncertainties, together with, however not restricted to, the potential usefulness, effectiveness, efficiency, security, medical advantages, medical response and the comfort of Viridian’s product candidates and the dangers set forth beneath Danger. Elements contained in our most up-to-date Quarterly Report on Type 10-Q filed with the Securities and Trade Fee (SEC) on November 12, 2024 and different subsequent disclosure paperwork filed with the SEC. Any forward-looking assertion speaks solely as of the date on which it’s made. Neither the Firm nor its associates, advisors or representatives undertake any obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as required by regulation requires it. These forward-looking statements shouldn’t be relied upon as representing the views of the Firm as of any date subsequent to the date hereof.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241213672239/en/
Anabel Chan, 617-458-8725
Vice President, Investor Relations and Communications
IR@viridiantherapeutics.com
Pierre Louisa, 617-272-4604
Supervisor, Investor Relations
IR@viridiantherapeutics.com
Supply: Viridian Therapeutics, Inc.
#Viridian #Therapeutics #Webcast #Veligrotug #Section #THRIVE2 #Topline #Outcomes #December #Investing.com , #Gossip247
,
